Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM).

Trial Profile

Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM).

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Dec 2011 Primary endpoint identified as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top